Comera Life Sciences Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMRA research report →
Price Chart
About the company
Comera Life Sciences Holdings, Inc. is an early-stage biotechnology firm focused on creating its own pipeline of innovative therapies. These treatments leverage its exclusive SQore formulation platform, engineered to transform intravenous (IV) biologic drugs into more convenient subcutaneous (SQ) injectable forms.
- CEO
- Michael G. Campbell
- IPO
- 2020
- Employees
- 12
- HQ
- Woburn, MA, US
Get TickerSpark's AI analysis on CMRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.07K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.02
- Div Yield
- 0.00%
- Gross Margin
- 66.77%
- Op Margin
- -1890.69%
- Net Margin
- -2843.79%
- ROE
- 47452.88%
- ROIC
- 1768.56%
Latest fiscal year · YoY change
- Revenue
- $633.10K+97.9%
- Gross Profit
- $422.71K+166.2%
- Op Income
- $-11,970,015
- Net Income
- $-18,004,098-230.2%
- EPS
- $-1.76-506.9%
- OCF Growth
- -160.0%
- FCF Growth
- -151.3%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.11
- RSI (14)
- 52
- Avg Volume
- 933
No earnings-call transcripts are available for CMRA yet.
- Free Float
- 44.0%
- Shares Outstanding
- 30.74M
- Float Shares
- 13.53M
of shares held by institutions
10 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Trustcore Financial Services, LLC | 43 | ▲ 43 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 29, 23 | Konar Shameek | buy | 4,090,908 |
| Dec 29, 23 | Konar Shameek | buy | 0 |
| Dec 27, 23 | Konar Shameek | other | 0 |
| Sep 11, 23 | Konar Shameek | other | 513,447 |
| Dec 29, 23 | DENNY GEORGE P III | buy | 3,913,526 |
| Dec 29, 23 | DENNY GEORGE P III | buy | 0 |
| Dec 27, 23 | DENNY GEORGE P III | other | 0 |
| Sep 11, 23 | DENNY GEORGE P III | other | 337,408 |
| Jan 4, 23 | DENNY GEORGE P III | other | 405,405 |
| Dec 27, 23 | HALPERN JOHN D | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CMRA coverage
Recent articles, reports, and earnings notes.
No research on CMRA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CMRA report →Actinium Pharmaceuticals (NYSE:ATNM) vs. Comera Life Sciences (NASDAQ:CMRA) Critical Comparison
defenseworld.net · Mar 5
Critical Contrast: Palatin Technologies (PINK:PTNT) vs. Comera Life Sciences (NASDAQ:CMRA)
defenseworld.net · Dec 30
Reviewing Comera Life Sciences (NASDAQ:CMRA) & Zymeworks (NYSE:ZYME)
defenseworld.net · Nov 17
Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option
globenewswire.com · Jan 4
Comera Life Sciences Announces Process Exploring Strategic Alternatives
globenewswire.com · Dec 6
Comera Life Sciences Appoints Dorothy Clarke to Board of Directors
globenewswire.com · Nov 13
Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights
globenewswire.com · Nov 9
Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference
globenewswire.com · Oct 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.